Literature DB >> 27456129

Tumor Necrosis Factor and Its Receptors Are Crucial to Control Mycobacterium bovis Bacillus Calmette-Guerin Pleural Infection in a Murine Model.

Leslie Chavez-Galan1, Dominique Vesin2, Noria Segueni3, Pritha Prasad2, Raphaële Buser-Llinares2, Guillaume Blaser2, Jean-Claude Pache4, Bernhard Ryffel3, Valérie F J Quesniaux3, Irene Garcia5.   

Abstract

Tumor necrosis factor (TNF) is crucial to control Mycobacterium tuberculosis infection, which remains a leading cause of morbidity and mortality worldwide. TNF blockade compromises host immunity and may cause reactivation of latent infection, resulting in overt pulmonary, pleural, and extrapulmonary tuberculosis. Herein, we investigate the roles of TNF and TNF receptors in the control of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleural infection in a murine model. As controls, wild-type mice and those with a defective CCR5, a receptor that is crucial for control of viral infection but not for tuberculosis, were used. BCG-induced pleural infection was uncontrolled and progressive in absence of TNF or TNF receptor 1 (TNFR1)/TNFR2 (TNFR1R2) with increased inflammatory cell recruitment and bacterial load in the pleural cavity, and heightened levels of pleural and serum proinflammatory cytokines and chemokines, compared to wild-type control mice. The visceral pleura was thickened with chronic inflammation, which was prominent in TNF(-/-) and TNFR1R2(-/-) mice. The parietal pleural of TNF(-/-) and TNFR1R2(-/-) mice exhibited abundant inflammatory nodules containing mycobacteria, and these mice developed nonresolving inflammation and succumbed from disseminated BCG infection. By contrast, CCR5(-/-) mice survived and controlled pleural BCG infection as wild-type control mice. In conclusion, BCG-induced pleurisy was uncontrolled in the absence of TNF or TNF receptors with exacerbated inflammatory response, impaired bacterial clearance, and defective mesothelium repair, suggesting a critical role of TNF to control mycobacterial pleurisy.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27456129     DOI: 10.1016/j.ajpath.2016.05.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  11 in total

1.  Mycobacterium tuberculosis Methyltransferase Rv1515c Can Suppress Host Defense Mechanisms by Modulating Immune Functions Utilizing a Multipronged Mechanism.

Authors:  Anshu Rani; Anwar Alam; Faraz Ahmad; Manjunath P; Abhinav Saurabh; Sheeba Zarin; Dipendra Kumar Mitra; Seyed E Hasnain; Nasreen Z Ehtesham
Journal:  Front Mol Biosci       Date:  2022-06-24

2.  Lipoarabinomannan Decreases Galectin-9 Expression and Tumor Necrosis Factor Pathway in Macrophages Favoring Mycobacterium tuberculosis Intracellular Growth.

Authors:  Leslie Chávez-Galán; Lucero Ramon-Luing; Claudia Carranza; Irene Garcia; Isabel Sada-Ovalle
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

3.  Association of VNTR polymorphism of tumor necrosis factor receptor 2 (TNFRSF1B) with pulmonary tuberculosis.

Authors:  Mohammad Naderi; Mohammad Hashemi; Nazanin Moradi
Journal:  Mol Biol Res Commun       Date:  2017-03

4.  Transmembrane TNF and Partially TNFR1 Regulate TNFR2 Expression and Control Inflammation in Mycobacterial-Induced Pleurisy.

Authors:  Husnu Uysal; Leslie Chavez-Galan; Dominique Vesin; Guillaume Blaser; Mahdia Benkhoucha; Bernhard Ryffel; Valérie F J Quesniaux; Irene Garcia
Journal:  Int J Mol Sci       Date:  2018-07-04       Impact factor: 5.923

5.  Myeloid cell TNFR1 signaling dependent liver injury and inflammation upon BCG infection.

Authors:  Leslie Chavez-Galan; Dominique Vesin; Guillaume Blaser; Husnu Uysal; Sulayman Benmerzoug; Stéphanie Rose; Bernhard Ryffel; Valérie F J Quesniaux; Irene Garcia
Journal:  Sci Rep       Date:  2019-03-28       Impact factor: 4.379

6.  Gene expression pattern analysis using dual-color RT-MLPA and integrative genome-wide association studies of eQTL for tuberculosis suscepitibility.

Authors:  Jing-Wen Ai; Hanyue Zhang; Zumo Zhou; Shanshan Weng; Heqing Huang; Sen Wang; Lingyun Shao; Yan Gao; Jing Wu; Qiaoling Ruan; Feifei Wang; Ning Jiang; Jiazhen Chen; Wenhong Zhang
Journal:  Respir Res       Date:  2021-01-20

7.  Leukocytes from Patients with Drug-Sensitive and Multidrug-Resistant Tuberculosis Exhibit Distinctive Profiles of Chemokine Receptor Expression and Migration Capacity.

Authors:  Ranferi Ocaña-Guzmán; Norma A Téllez-Navarrete; Lucero A Ramón-Luing; Iliana Herrera; Marlon De Ita; José-Luis Carrillo-Alduenda; José Alberto Choreño-Parra; Karen Medina-Quero; Joaquín Zúñiga; Leslie Chávez-Galán
Journal:  J Immunol Res       Date:  2021-04-21       Impact factor: 4.818

8.  Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time.

Authors:  Norma A Téllez-Navarrete; Lucero A Ramon-Luing; Marcela Muñoz-Torrico; Mario Preciado-García; Karen Medina-Quero; Rogelio Hernandez-Pando; Leslie Chavez-Galan
Journal:  Mol Med       Date:  2021-07-14       Impact factor: 6.354

9.  Transmembrane Tumor Necrosis Factor Controls Myeloid-Derived Suppressor Cell Activity via TNF Receptor 2 and Protects from Excessive Inflammation during BCG-Induced Pleurisy.

Authors:  Leslie Chavez-Galan; Dominique Vesin; Husnu Uysal; Guillaume Blaser; Mahdia Benkhoucha; Bernhard Ryffel; Valérie F J Quesniaux; Irene Garcia
Journal:  Front Immunol       Date:  2017-08-25       Impact factor: 7.561

10.  CD3+ Macrophages Deliver Proinflammatory Cytokines by a CD3- and Transmembrane TNF-Dependent Pathway and Are Increased at the BCG-Infection Site.

Authors:  Adriana Rodriguez-Cruz; Dominique Vesin; Lucero Ramon-Luing; Joaquin Zuñiga; Valérie F J Quesniaux; Bernhard Ryffel; Ricardo Lascurain; Irene Garcia; Leslie Chávez-Galán
Journal:  Front Immunol       Date:  2019-11-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.